Well, they (Mizuho Securities) must have felt "strongly", after the CRL for ZS-9, that RLYP would be bought (or even before ?). She did her part by getting the "sell" out there which helped lower the PPS Anyway, that director that bought 30K in March did OK.
Guess who bought 219K RLYP shares in the 2nd quarter? All the while her company was BASHING Relypsa! Maybe it was just dumb luck or she is as crooked as Berens.
Not sure if its over but DOUBT still remains:
"Galenica Slides Amid Doubts About Relypsa Deal -- Market Talk
BY Dow Jones & Company, Inc.
— 12:03 PM ET 07/21/2016
1603 GMT - Shares in Swiss conglomerate Galenica ( GNHAF)
slid 11% on word it will pay $1.5B for US biotech Relypsa ( RLYP )
ahead of the company's planned splitoff of its Vifor pharmaceuticals business. The slide suggests investors believe Galenica ( GNHAF ) paid too much, says EP Vantage. Relypsa's Veltassa, a new treatment for a potentially fatal blood condition called hyperkalemia, has a black-box warning because of safety concerns, analysts say its launch has been slow and competition could come from an AstraZeneca (AZN) drug in development." REALLY???
"Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Relypsa, Inc. (NASDAQ: RLYP) breached their fiduciary duties in connection with the proposed sale of the Company to Galenica.
Additional Information: Relypsa is a biopharmaceutical company that focuses on the discovery, development and commercialization of polymeric medicines for patients with conditions that are overlooked and undertreated and can be addressed in the gastrointestinal tract.
On July 21, 2016, Relypsa announced it had signed a definitive merger agreement with Galenica. Under the terms of the agreement, Galenica will pay $32.00 per share in cash for each share of Relypsa common stock.
The investigation concerns whether the Relypsa board failed to satisfy their duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Relypsa shares of common stock. Nationally recognized Johnson & Weaver is investigating whether the proposed deal price represents adequate consideration; especially given that the price target for one Wall Street analyst is $51.00. The 52-week high for Relypsa stock is $35.97. "
thx (LOL) Where is Lurker? He should not be depressed anymore right? Golong should be happy since Orwin finally listened to him!
The overall issue is the tutes that bought above $32 last Match-June (2015). They will lose a few million. Maybe Orbimed comes out OK but not sure of many others. Also, Galenica avoids (if they still own VF) any more royalties for the EU and they acquire the cash and residual debt beneficially too. This price seems low in that case (too). In either case, CONGRATS to all that held through the last 9 months - the CLOWN show closes now(?)
investorvillage is a good alternative (too) but either way this MSB has been somewhat disintegrated due to Yahoo's intelligence!!!
gamebirdy - "fatigued" is the word most feel. AND despite the DOW and S&P getting into record territory, the IBB (Bios) and the NASDAQ overall (small caps) are severely lagging which pulls down RLYP and a few others from gaining momentum. Good luck!
But we won't see July or August or September until after 3rd Qtr is complete (sometime in October). Quarterly going forward after today.
I bought his shares for $18.35 - might regret that but I want to have a few more for next week - in case anything good occurs. The darn stock dropped $1 off its high right after that!!!
Yep - IBB has fully recovered from last Thursday's close of 262+.Nasdaq is close (within 40pts) of last Thursday's close. Maybe we can breathe easier this weekend? Still might be a bit of profit taking this afternoon.
While the IBB is 5 pts short (was 262). Not sure there will be a "complete" recovery as many daytraders or weekly traders will cash out their gains after Monday (either late today or Friday).